The effect of curcumin on hepatic fat content in individuals with obesity

Hellmann, Pernille H; Carlander, Katrine R; Forman, Julie Lyng; Chabanova, Elizaveta; Svenningsen, Jens S.; Holst, Jens J.; Gillum, Matthew P.; Vilsbøll, Tina; Knop, Filip K.

doi:10.1111/dom.14804

Cited by 10 publications

(3 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of curcumin on circulating glucagon concentrations is uncertain and the present results indicate that curcumin does not affect prednisolone-induced hyperglucagonaemia in humans. A previous study by our group in obese individuals showed no effects of curcumin on circulating glucagon concentrations after 6 weeks treatment ( 45 ).…”

Section: Discussionmentioning

confidence: 74%

No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity

Hellmann

Carlander

Hansen

et al. 2023

Endocrine Connections

Self Cite

View full text Add to dashboard Cite

Objectives: Preclinically, curcumin has been shown to protect against glucocorticoid-induced insulin resistance. We evaluated the effect of curcumin administered with prednisolone in healthy overweight or obese men. Methods: In a double-blind, parallel-group trial, 24 overweight/obese non-diabetic men were randomised to one of three intervention groups A) prednisolone placebo+curcumin placebo, B) prednisolone (50 mg/day)+curcumin placebo or C) prednisolone and curcumin (400 mg/day). Curcumin or curcumin placebo treatment started one day prior to 10-day prednisolone or prednisolone placebo treatment. The primary endpoint was change in prednisolone-induced insulin resistance assessed by homeostatic model assessment of insulin resistance (HOMA2-IR). Other endpoints included anthropometric measurements, magnetic resonance spectroscopy-assessed hepatic fat content, blood pressure, circulating metabolic markers and continuous glucose monitoring measures. Results: Baseline characteristics (mean ± SD): age 44.2 ± 13.7 years, body mass index 30.1 ± 3.5 kg/m2, glycated haemoglobin A1c 33.3 ± 3.2 mmol/mol, HOMA2-IR 1.10 ± 0.45 and fasting plasma glucose 5.2 ± 0.4 mmol/L. Prednisolone significantly increased HOMA2-IR (estimated treatment difference 0.36 [95% CI 0.16; 0.57]). Co-treatment with curcumin had no effect on HOMA2-IR (estimated treatment difference 0.08 [95% CI −0.13; 0.39]). Prednisolone increased glycated haemoglobin A1c, insulin, C-peptide, glucagon, blood pressure, mean interstitial glucose, time spent in hyperglycaemia and glucose variability, but no protective effect of curcumin on any of these measures was observed. Conclusions: In this double-blind, placebo-controlled parallel-group study involving 24 overweight or obese men randomised to one of three treatment arms, curcumin treatment had no protective effect on prednisolone-induced insulin resistance or other gluco-metabolic perturbations.

show abstract

Section: Discussionmentioning

confidence: 74%

No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity

Hellmann

Carlander

Hansen

et al. 2023

Endocrine Connections

Self Cite

View full text Add to dashboard Cite

show abstract

“…In humans, reports of the effect of curcumin on anthropometric parameters have been carried out in trials with patients with overweight or obesity combined with other pathologies. Although many studies have reported that curcumin reduces waist circumference [ 181 , 182 ] in patients with grade III obesity, no significant decrease in this variable or visceral fat was found [ 183 ]. In some clinical trials and meta-analyses, no significant reductions in BMI and weight have been found [ 181 ]; however, when performing the statistical analysis by groups, a decrease was found [ 182 ].…”

Section: Molecules With Demonstrated Clinical Efficacy In the Prevent...mentioning

confidence: 99%

Clinically Effective Molecules of Natural Origin for Obesity Prevention or Treatment

Hidalgo-Lozada,

Villarruel-López,

Nuño

et al. 2024

IJMS

View full text Add to dashboard Cite

The prevalence and incidence of obesity and the comorbidities linked to it are increasing worldwide. Current therapies for obesity and associated pathologies have proven to cause a broad number of adverse effects, and often, they are overpriced or not affordable for all patients. Among the alternatives currently available, natural bioactive compounds stand out. These are frequently contained in pharmaceutical presentations, nutraceutical products, supplements, or functional foods. The clinical evidence for these molecules is increasingly solid, among which epigallocatechin-3-gallate, ellagic acid, resveratrol, berberine, anthocyanins, probiotics, carotenoids, curcumin, silymarin, hydroxy citric acid, and α-lipoic acid stand out. The molecular mechanisms and signaling pathways of these molecules have been shown to interact with the endocrine, nervous, and gastroenteric systems. They can regulate the expression of multiple genes and proteins involved in starvation–satiety processes, activate the brown adipose tissue, decrease lipogenesis and inflammation, increase lipolysis, and improve insulin sensitivity. This review provides a comprehensive view of nature-based therapeutic options to address the increasing prevalence of obesity. It offers a valuable perspective for future research and subsequent clinical practice, addressing everything from the molecular, genetic, and physiological bases to the clinical study of bioactive compounds.

show abstract

“…The trials listed on clinicaltrials.gov report the use of capsules or tablets of curcumin alone or of phospholipids and curcumin together (see Table 4 ). In particular, trials evaluating the efficacy and safety of curcumin in both NAFLD and obese patients at different doses [ 280 , 281 ] assessed both the reduction in fibrosis by the use of Fibroscan [ 280 ] and serum levels of inflammatory markers or fat/glucose parameters [ 281 ], but these results were not significantly different from those observed in the placebo group.…”

Section: Possible Therapeutic Approachesmentioning

confidence: 99%

Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD

Vitulo

Gnodi

Rosini

et al. 2023

IJMS

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD, including nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH)) is a high-prevalence disorder, affecting about 1 billion people, which can evolve to more severe conditions like cirrhosis or hepatocellular carcinoma. NAFLD is often concomitant with conditions of the metabolic syndrome, such as central obesity and insulin-resistance, but a specific drug able to revert NAFL and prevent its evolution towards NASH is still lacking. With the liver being a key organ in metabolic processes, the potential therapeutic strategies are many, and range from directly targeting the lipid metabolism to the prevention of tissue inflammation. However, side effects have been reported for the drugs tested up to now. In this review, different approaches to the treatment of NAFLD are presented, including newer therapies and ongoing clinical trials. Particular focus is placed on the reverse cholesterol transport system and on the agonists for nuclear factors like PPAR and FXR, but also drugs initially developed for other conditions such as incretins and thyromimetics along with validated natural compounds that have anti-inflammatory potential. This work provides an overview of the different therapeutic strategies currently being tested for NAFLD, other than, or along with, the recommendation of weight loss.

show abstract

The effect of curcumin on hepatic fat content in individuals with obesity

Cited by 10 publications

References 80 publications

No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity

No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity

Clinically Effective Molecules of Natural Origin for Obesity Prevention or Treatment

Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD

Contact Info

Product

Resources

About